Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Rheumatol Int ; 44(11): 2645-2652, 2024 Nov.
Article in English | MEDLINE | ID: mdl-39249142

ABSTRACT

Anti-synthetase syndrome (AS) is a subset of idiopathic inflammatory myopathy (IIM) characterized by the presence of anti-aminoacyl-transfer RNA synthetase accompanied by myositis, interstitial lung disease and other clinical features. According to a recent multicentric study, 31% of AS patients present skin lesions compatible with dermatomyositis, but sclerodermiform features are rare. Therefore, we aimed to report the case of a patient with simultaneous diagnosis of AS, deep morphea, vasculitic neuropathy, and myelodysplastic syndrome and review the current literature regarding these uncommon associations. A 57 year old man with axial and symmetrical proximal muscle weakness, skin thickening and B symptoms, later diagnosed with PL7 + AS, deep morphea, myelodysplastic syndrome (MDS) and vasculitic neuropathy documented by histopathologic studies and immunologic assessments. Since both AS and deep morphea share the vasculopathic changes and type II interferon-induced inflammation, we hypothesize that they may share pathogenic mechanisms. The muscle biopsy of the patient was consistent with AS and showed focal neutrophil infiltration. The patient received intensive immunosuppressive therapy for AS and vasculitic neuropathy, with high dose steroids, intravenous immunoglobulin (IVIg) and rituximab. Nonetheless, he suffered an unfavorable evolution with a fatal outcome due to septic shock. Albeit sclerodermiform features are rare in patients with AS, we propose a pathogenic link among AS, deep morphea and the autoimmune/autoinflammatory signs of MDS. The vasculopathic changes along with the activation of the innate and adaptive immune system leading to the production of proinflammatory cytokines may have been one of the contributing factors for the coexisting diagnosis of the patient.


Subject(s)
Myelodysplastic Syndromes , Myositis , Scleroderma, Localized , Humans , Male , Middle Aged , Myositis/immunology , Myositis/drug therapy , Myositis/diagnosis , Scleroderma, Localized/drug therapy , Scleroderma, Localized/immunology , Scleroderma, Localized/pathology , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/diagnosis , Fatal Outcome , Immunosuppressive Agents/therapeutic use , Autoantibodies/blood , Amino Acyl-tRNA Synthetases/immunology
2.
Adv Rheumatol ; 59(1): 19, 2019 05 14.
Article in English | MEDLINE | ID: mdl-31088556

ABSTRACT

OBJECTIVE: To evaluate the frequency of anti-collagen type V in humans with early systemic sclerosis (SSc) compared to defined SSc patients and healthy controls, since collagen type V was shown to be overexpressed in early SSc patients' skin and there is no data concerning the presence of this antibody in early stages of human SSc. Experimental studies showed that animal models immunized with collagen type V developed a disease similar to human systemic sclerosis (SSc), with antibodies production, mainly in early stages post-immunization. METHODS: Eighty-one female SSc patients were included and divided into two groups: early-SSc (18 patients-EULAR Preliminary Criteria) and defined-SSc (63 patients-ACR Criteria 1980). The control group consisted of 19 healthy women age-matched to Early-SSc group. Anti-collagen type V was performed by ELISA. Data was analyzed by appropriate tests. RESULTS: The prevalence of anti-collagen type V in early-SSc, defined-SSc and control groups was respectively 33, 17 and 5% (p = 0.07). SSc patients with anti-collagen type V had shorter disease duration compared to those without this antibody (8.8 ± 5.1 vs. 14.7 ± 8.9, p = 0.006). Likewise, early-SSc patients with anti-collagen V also had a shorter disease duration than patients negative for this antibody (4.6 ± 2.2 vs. 9.7 ± 5.2, p = 0.04). No association with clinical subsets or scleroderma antibodies specificities was observed (p > 0.05). CONCLUSION: The production of anti-collagen type V in SSc seems to be an early event independent of other antibodies specificities. Further studies are necessary to determine if the underlying mechanism for this chronology involves a primary immune response to abnormal expression of collagen type V.


Subject(s)
Antibodies/analysis , Collagen Type V/immunology , Scleroderma, Diffuse/immunology , Scleroderma, Limited/immunology , Adult , Age Factors , Antibodies, Antinuclear/analysis , Biomarkers/analysis , Case-Control Studies , Collagen Type V/analysis , Cross-Sectional Studies , Female , Humans , Middle Aged , Scleroderma, Localized/immunology
3.
Int J Dermatol ; 53(8): 947-51, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24527729

ABSTRACT

BACKGROUND: Progressive hemifacial atrophy or Parry-Romberg Syndrome (PRS) is a rare, acquired, progressive dysplasia of subcutaneous tissue and bone characterized by unilateral facial involvement. Its etiology is unknown, but theories about its pathogenesis include infectious, degenerative, autoimmune, and traumatic causes among others. The causal relationship of PRS and linear morphea en coup de sabre (LMCS) with Borrelia burgdorferi infection remains controversial. Our goal was to serologically determine anti-B. burgdorferi antibodies in patients diagnosed with PRS and LMCS to establish a possible association as a causative agent. METHODS: We conducted a serology study with patients belonging to a group of 21 individuals diagnosed with PRS, six with LMCS, and 21 matched controls. Anti-Borrelia IgG antibodies were determined by ELISA. A descriptive statistical analysis and Fischer's exact test were done. RESULTS: In serological tests, only two cases had borderline values and were further analyzed by Western blot with non-confirmatory results. For both the PRS and LMCS group, the association test was not significant, suggesting a lack of association between PRS or LMCS and the presence of anti-Borrelia antibodies. CONCLUSION: In Mexico there are no previous studies on Borrelia infection and its relationship between PRS or LMCS. Our result showed a lack of association of either clinical entities with anti-Borrelia-antibodies. Former reports of this association may suggest coincidental findings without causal relationship.


Subject(s)
Antibodies, Bacterial/blood , Borrelia burgdorferi/immunology , Facial Hemiatrophy/immunology , Immunoglobulin G/blood , Scleroderma, Localized/immunology , Adolescent , Adult , Aged , Case-Control Studies , Child , Facial Hemiatrophy/epidemiology , Facial Hemiatrophy/microbiology , Female , Humans , Lyme Disease/complications , Male , Mexico/epidemiology , Middle Aged , Scleroderma, Localized/epidemiology , Scleroderma, Localized/microbiology , Seroepidemiologic Studies , Young Adult
4.
Autoimmun Rev ; 12(11): 1064-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23791631

ABSTRACT

INTRODUCTION: Scleroderma featuring rare connective tissue disease that manifests as skin sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis and visceral involvement and localized scleroderma or morphea which classically presents benign evolution and self-limited, confined to the skin and/or underlying tissue. Recent studies show that the localized form may possibly course with involvement of internal organs and variable morbidity. This study aimed to determine the demographic characteristics, the prevalence of systemic manifestations and laboratory findings, as well as the association with autoimmune diseases, and the evolution of neurological findings, both clinical as brain MRI in patients with scleroderma of the face and its relation with the activity skin. METHODS: Patients with localized scleroderma with facial involvement were evaluated and underwent neurological examination, magnetic resonance imaging and ophthalmology evaluation. After 3years, the patients were subjected again to MRI. RESULTS: We studied 12 patients with localized scleroderma of the face. Of this total, headache being the most frequent complaint found in 66.7% of patients, 33.3% had neurological changes possibly associated with scleroderma. As for ophthalmologic evaluation, 25% of patients showed abnormalities. The most frequent parenchymal finding was the presence of lesions with hyperintense or hypointense signal in 75% of patients, followed by ventricular asymmetry at 16.7%. Of the patients who had neurological deficits, 75% also had a change to MRI. In all patients, imaging findings after 3years were unchanged. During this interval of 3years, 25% of patients showed signs of activity of scleroderma. CONCLUSION: Patients with localized scleroderma of the face have a high prevalence of neurological and ophthalmological changes. Based on these findings, we suggest that all cases of localized scleroderma of the face should be thoroughly examined for the presence of systemic changes.


Subject(s)
Autoimmune Diseases/complications , Face/pathology , Scleroderma, Localized/complications , Autoimmune Diseases/diagnostic imaging , Autoimmune Diseases/immunology , Collagen/metabolism , Humans , Magnetic Resonance Imaging , Prevalence , Prospective Studies , Radiography , Scleroderma, Localized/diagnostic imaging , Scleroderma, Localized/immunology , Skin/diagnostic imaging , Skin/immunology , Skin/pathology , Treatment Outcome
5.
Int J Dermatol ; 50(11): 1373-1378, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22004491

ABSTRACT

BACKGROUND: In the present study, Borrelia spirochetes were found in four (26.6%) out of 15 patients with Atrophoderma of Pasini and Pierini (IAPP) and lichen sclerosis et atrophicans (LSA) from the Brazilian Amazon Region. MATERIAL AND METHODS: Borreliosis was investigated by immunohistochemistry and focus floating microscopy for Borrelia burgdorferi in skin biopsy samples from 15 patients with both clinical and histopathology evidences compatible with Morphea, LSA, and IAPP. RESULTS: Spirochetes were detected by specific immunohistochemistry and focus floating microscopy for B. burgdorferi in samples from three patients. A limitation of our study was the fact that we were not able to isolate and culture these organisms. CONCLUSION: Our data confirm the presence of borreliosis cases in the Amazon.


Subject(s)
Borrelia burgdorferi Group/isolation & purification , Scleroderma, Localized/microbiology , Scleroderma, Localized/pathology , Adolescent , Adult , Antigens, CD20 , B-Lymphocytes/immunology , Brazil/epidemiology , Female , Humans , Immunohistochemistry , Lichen Sclerosus et Atrophicus/microbiology , Male , Microscopy , Middle Aged , Scleroderma, Localized/immunology , Young Adult
6.
Clin Rheumatol ; 29(9): 1055-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20549277

ABSTRACT

Morphea is a disease that affects connective tissue and microvessels. Its pathogenesis is unknown, but several autoimmune factors participate. Our objective was to determine the frequency of antinuclear antibodies (ANAs) in pediatric patients with morphea and to establish their relation with the clinical variants and disease activity. A cross-sectional study was carried out from January 1999 to January 2008 in patients with morphea seen at the Instituto Dermatologico de Jalisco. ANAs were determined through an indirect immunoflourescent method, and the immunospecificity was done with a double immunodiffusion technique in agarose gel. A total of 34 children were included in the study, 74% of the female gender. Plaque morphea was the most common variant, present in 44% of the cases, followed by linear morphea in 38%, and generalized morphea in 18%. ANAs were positive in 29%, with homogenous immunoflourescense as the most frequent pattern (70%). Of the ANA-positive patients, 83% had generalized morphea, and in 70% of the cases the disease were considered as active. The frequency of ANA-positive children with morphea was 29%, and seems to be related to more extensive disease. No previous studies exist on this topic in the mestizo Mexican population.


Subject(s)
Antibodies, Antinuclear/blood , Scleroderma, Localized/ethnology , Scleroderma, Localized/immunology , Adolescent , Biomarkers/blood , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Male , Mexico , Retrospective Studies , Scleroderma, Localized/blood , Severity of Illness Index
7.
Rev Alerg Mex ; 56(4): 136-45, 2009.
Article in Spanish | MEDLINE | ID: mdl-19768975

ABSTRACT

It has been described two main phenotypes of helper T cells. On activation, the immune system develops the most effective Th response. Whereas Th1 cells promote cell-mediate immunity against intracellular pathogens and an over expression could favor autoimmune diseases; Th2 cells develop humoral immunity against extracellular pathogens promoting allergic response. Normally, the two profiles coexist in the same individual with different grades of expression. Recently, it has been described a new subset: Th17, which is related to tissue injury in autoimmune diseases. Then, allergic and autoimmune diseases result from an unbalanced response of the immune system. Allergen-specific immunotherapy is the only curative treatment of a specific allergy, which leads to a life-long tolerance against allergens. There are no controlled studies about the effectiveness or risks associated with allergen-specific immunotherapy in patients with autoimmune disorders. On the other hand, scleroderma is an autoimmune chronic systemic disorder of unknown etiology characterized by excess collagen deposition in the skin and viscera, along with vascular injury. We report a girl with allergic asthma and with a second degree family history of systemic sclerosis who developed localized scleroderma during allergen specific immunotherapy. Because allergy vaccination alter the balance between effector and regulatory T-cell populations, which regulate immune tolerance, a positive family history of autoimmunity in first or second degree, could be a contraindication for allergen-specific immunotherapy.


Subject(s)
Desensitization, Immunologic/adverse effects , Scleroderma, Localized/etiology , Abdomen , Asthma/complications , Asthma/therapy , Child , Contraindications , Family Health , Female , Genetic Predisposition to Disease , Humans , Models, Immunological , Scleroderma, Localized/genetics , Scleroderma, Localized/immunology , Scleroderma, Systemic/genetics , Sinusitis/complications , T-Lymphocyte Subsets/classification , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Helper-Inducer/classification , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Regulatory/immunology
8.
Int J Dermatol ; 42(11): 882-6, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14636204

ABSTRACT

BACKGROUND: Morphea and lichen sclerosus et atrophicus (LSA) are sclerotic skin lesions of unknown etiology involving connective tissue. The hypothesis of a borrelial origin of morphea and LSA is currently controversial. METHODS: Immunoglobulin G (IgG) immunoblot serologies against Borrelia burgdorferi in patients with morphea and LSA were analyzed and compared with those from healthy donors and patients with syphilis to determine the association with a probable borrelial agent in Colombia. RESULTS: No significant differences in the number of reactive antigenic bands were found between morphea/LSA patients and syphilis patients or healthy donors. The presence of at least one of the following bands, p28, p39, or p45, was the criterion most able to distinguish morphea/LSA, yielding a specificity of 95% and a sensitivity of 28.6%. Using this criterion as evidence of putative exposure to a causative borrelial agent, sclerotic skin lesions had an odds ratio of 7.60 (95% confidence interval, 1.47-39.23). CONCLUSIONS: These results could be explained by cross-reactivity; however, the partial shared reactivity of sera from patients with syphilis and morphea/LSA does not rule out the possibility that a new spirochetal agent, unrelated to B. burgdorferi or Treponemas, may be the causative agent of morphea/LSA in Colombia.


Subject(s)
Antibodies, Bacterial/blood , Borrelia burgdorferi/immunology , Immunoglobulin G/blood , Lichen Sclerosus et Atrophicus/microbiology , Scleroderma, Localized/microbiology , Adolescent , Adult , Child , Child, Preschool , Colombia , Cross Reactions , Female , Humans , Lichen Sclerosus et Atrophicus/immunology , Male , Middle Aged , Scleroderma, Localized/immunology , Syphilis/immunology , Syphilis/microbiology
10.
J Rheumatol ; 22(1): 73-7, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7699686

ABSTRACT

OBJECTIVE: To determine autoantibody profiles of patients with Parry-Romberg syndrome (PRS). METHODS: Antinuclear antibodies (ANA) in 14 patients with PRS were studied by indirect immunofluorescence (IIF), immunodiffusion and immunoblotting. Antinative DNA antibodies and rheumatoid factor (RF) were also analyzed. RESULTS: ANA were positive in 8 patients (57%). The patterns of staining included nucleolar, nuclear speckled and homogeneous. Anticentromere antibodies were observed in 2 and antihistone antibodies in 3 sera. Rheumatoid factor was found in 5 (36%) sera. Antinative DNA or antibodies that precipitated rabbit thymus extract were not found in any patients. CONCLUSION: The serologic abnormalities observed in this study suggests that autoimmunity could play a pathogenic role in PRS.


Subject(s)
Antibodies, Antinuclear/blood , Scleroderma, Localized/immunology , Adolescent , Adult , Animals , Antigens, Protozoan , Centromere/immunology , Child , Crithidia , Female , Histones/immunology , Humans , Immunoblotting , Incidence , Male , Rheumatoid Factor/blood , Scleroderma, Localized/blood
SELECTION OF CITATIONS
SEARCH DETAIL